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February 2016 Abstracts S37vomiting (25%), and fatigue (23%). Most AEs were
Grade (G) 1-2. The G3 treatment-related AEs were rash
(6 pts), fatigue (1 pt), decreased appetite (1 pt), dehy-
dration (1 pt), pruritus (1 pt), and face edema (1 pt). In
particular, no G3 treatment-related gastrointestinal
toxicity or liver enzyme elevation has been reported. To
date, 24 ALKþ NSCLC pts treated at doses  200 mg are
evaluable for response; partial response (PR) was
achieved in 16 pts (67%) and stable disease (SD) in 3 pts
(13%). In the crizotinib-naïve pts (n¼8), responses were
observed in 6 pts (75%) and SD in 1 pt (13%). In the 12
pts with prior crizotinib but no other ALK TKI, 10 pts
(83%) achieved PR and 1 (8%) SD. CNS responses have
been observed in both crizotinib naïve and crizotinib
resistant pts. The median duration of treatment in the 24
evaluable ALKþ pts is 23.8þ weeks, with the longest
being 112þ weeks.
Conclusion: X-396 is well-tolerated and induces re-
sponses in both crizotinib-naïve and crizotinib-resistant
ALKþ NSCLC pts, as well as patients with CNS lesions.
Enrollment is ongoing in the expansion cohorts.
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Introduction: Approximately 30% of patients with an
adenocarcinoma have a druggable driver mutation.
However, the access to tumor tissue to perform the
molecular proﬁle is often limited. Circulating tumor DNA
(ctDNA) can be used for detection and quantiﬁcation of
molecular abnormalities as a non-invasive tool. We
performed a retrospective study to assess the concor-
dance in molecular alterations between tissue biopsies
and ctDNA in 20 NSCLC patients as well as the impact of
treatment on ctDNA proﬁle.
Methods: Plasma samples were collected from 17
consecutive treatment-naïve and 3 pre-treated advanced
NSCLC patients from Gustave Roussy. For 10 patients a
second blood sample was collected 21 days after starting
chemotherapy to monitor the mutational proﬁle. DNA
was extracted from < 3 ml plasma and analyzed using
the enhanced Tam-SeqTM assay covering regions
from 35 genes. TAM-Seq data (generated using Illuminasequencing) were compared to a different NGS platform
(Ion-torrent) as well as Sanger sequencing data from
tissue biopsy samples analyzed in routine daily clinical
practice.
Results: From May 2015 to June 2015, 20 patients were
included (70% were male, 15% never-smoker, 75% had
an adenocarcinoma subtype, and 70% a stage IV). Only
40% of tumor biopsies provided sufﬁcient sample tissue
for molecular analysis. ctDNA proﬁling was possible for
all patients, which detected cancer mutations in 19 out
of 20 patients. Median number of mutations in plasma
was 2, predominantly located in KRAS, TP53 and EGFR
mutation. Half of the mutations detected in ctDNA were
observed at a frequency lower than 1%. In 10 NSCLC
patients dynamic ctDNA changes after 21 days of treat-
ment were evaluated. No new mutations were detected
at day 21. Seven out of 10 patients experienced a partial
response in CT scan by RECIST criteria. All of them had
either a lower frequency of mutations or undetectable
levels of mutations at day 21.
Conclusions: ctDNA can be used as a ‘liquid biopsy’ for
molecular proﬁling of mutations in NSCLC patients in the
absence of an invasive biopsy with a high concordance
with tissue genomic proﬁle. Also, ctDNA can potentially
be used as a surrogate marker of response. Update in 35
patients will be presented during the conference.
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Lung cancer is the leading cause of cancer-related
deaths globally. Despite advances in treatment with
targeted therapies and earlier detection, the 5-year
survival rate remains a dismal 15%. Due to the low
survival rate, there is a critical need for new therapies
targeting lung cancer. Most lung cancers have
increased activation of Wnt signaling and/or Wnt
protein expression, which makes Wnt a strong po-
tential target for the development of new lung cancer
therapeutics. Triptolide is a natural compound isolated
from the Thunder God Vine, Tripterygium wilfordii,
which has been used in traditional Chinese medicine
to treat autoimmune disorders and inﬂammation. We
previously showed that triptolide increases WIF1
expression by decreasing WIF1 promoter methylation,
thereby inhibiting the Wnt pathway. Though triptolide
S38 Journal of Thoracic Oncology Vol. 11 No. 2Shas potent anti-tumor activity, it has limited clinical
use due to its toxicity. Derivatives of triptolide have
been developed in order to decrease toxicity without
affecting bioavailability. One of these triptolide de-
rivatives, MRx102, has been shown to have antileu-
kemic activity, but the effect of MRx102 in lung cancer
is currently unknown. In this study, we evaluated
MRx102 as a novel therapeutic for lung cancer. We
tested the effect of MRx102 on the proliferation and
survival of non-small cell lung cancer (NSCLC) cell
lines in vitro and the effect on tumor formation and
metastasis in vivo. Mice injected subcutaneously with
H460 lung cancer cells were treated with MRx102 or
carboplatin to determine the effect of MRx102 on tu-
mor formation in comparison to standard treatment.
Patient-derived xenografts (PDX) with different WIF1
expression levels were treated with MRx102 or
cisplatin. We then tested the effects of MRx102
treatment on migration and invasion of lung cancer
cells using Transwell ﬁlters coated with ﬁbronectin
and Matrigel, respectively. Tail vein injections of H460
and A549 cells were used to study the effect of
MRx102 on metastasis. Our studies show the MRx102
decreases proliferation of both H460 and A549 lung
cancer cells and increases apoptosis in the H460 cell
line. Further, MRx102 also signiﬁcantly inhibited
migration and metastasis. We also have shown that
MRx102 potently inhibits the growth of tumors with
low WIF1 expression and decreases Wnt pathway ac-
tivity in vitro. These results indicate that MRx102 has
potent antitumor effects in lung cancer both in vitro
and in vivo, and is a potential novel therapy that tar-
gets the Wnt pathway in NSCLC.Gene expression classiﬁer for
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Medicine of Cancer (IMPPC), Barcelona, SpainPatients with resected stage II and IIIA non-small cell
lung carcinoma (NSCLC) are eligible for adjuvant
chemotherapy, however its efﬁcacy for stage I patients
is still ambiguous. Importantly, adjuvant chemo-
therapy trials in early stage lung cancer patients have
been conducted in unselected patient populations,
which may, in part, explain the lack of conclusive ev-
idence of beneﬁt. There are currently no validated
methods that prospectively identify NSCLC patients at
a high risk of recurrence after surgery. Many gene
expression-based gene signatures that identify pa-
tients with lung adenocarcinoma (ADC) at high-risk of
recurrence have been described. However, data are
still lacking on molecular signatures that stratify risk
of recurrence in patients with Squamous Cell Carci-
noma (SCC), the second most common histological
subtype of NSCLC. SCC is commonly detected in heavy
smokers, where the risk of lung cancer is closely
correlated with tobacco consumption. The disease is
heterogeneous, and patient outcome is complicated by
comorbities such as Chronic Obstructive Pulmonary
Disease and Cardiovascular Disease. The National Lung
Screening Trial (NLST), which compared low-dose
computed tomography (LDCT) versus chest radiog-
raphy, demonstrated a statistically signiﬁcant mortal-
ity beneﬁt of LDCT screening in patients with ADC.
However, there was no beneﬁt for patients with lung
SCC despite an increase in the detection of early stage
tumors. Surgical resection is the recommended treat-
ment for Stage I NSCLC. However, approximately 30%
patients will recur and die within 5 years of surgery.
In view of the high rate of relapse and the lack of
predictive biomarkers, it is critical to develop bio-
markers that can identify high-risk early stage lung
cancer patients who may beneﬁt from adjuvant
chemotherapy or immunotherapy. We present a
prognostic classiﬁer based on gene expression that is
broadly applicable to diverse patient cohorts as a
clinical tool for guiding postoperative management
and therapeutic decisions in patients with early stage
lung SCC. In order to maximize the potential for
discovering functionally relevant biomarkers we
focused our study on genes with known mechanistic
roles in lung SCC development and prognosis. Specif-
ically, the expression of 256 genes selected by a
literature search was evaluated in microarrays from
107 tumors resected from patients with early stage
lung SCC. Genes signiﬁcantly associated with relapse-
free survival by univariable Cox regression were
technically validated by qRT-PCR in the same sample
population and externally validated in an indepen-
dently collected cohort of 91 SCC. A multivariable
regression-based classiﬁer was then established on
genes independently associated with survival in these
